Revenue Breakdown
Composition ()
No data
Revenue Streams
Cryo-Cell International Inc (CCEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Processing and storage fees, accounting for 99.3% of total sales, equivalent to $7.87M. Other significant revenue streams include Public banking revenue and Product revenue. Understanding this composition is critical for investors evaluating how CCEL navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Cryo-Cell International Inc maintains a gross margin of 74.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.29%, while the net margin is 9.58%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CCEL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CCEL competes directly with industry leaders such as SWVL and BTOC. With a market capitalization of $27.55M, it holds a leading position in the sector. When comparing efficiency, CCEL's gross margin of 74.61% stands against SWVL's 21.48% and BTOC's -5.02%. Such benchmarking helps identify whether Cryo-Cell International Inc is trading at a premium or discount relative to its financial performance.
